CARDIOVASCULAR DRUGS AND THERAPY

metrics 2024

Pioneering the future of cardiovascular pharmacology.

Introduction

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Metrics 2024

SCIMAGO Journal Rank0.97
Journal Impact Factor3.10
Journal Impact Factor (5 years)3.30
H-Index79
Journal IF Without Self3.10
Eigen Factor0.00
Normal Eigen Factor0.82
Influence0.82
Immediacy Index0.50
Cited Half Life4.90
Citing Half Life5.80
JCI0.80
Total Documents1988
WOS Total Citations3282
SCIMAGO Total Citations13353
SCIMAGO SELF Citations379
Scopus Journal Rank0.97
Cites / Document (2 Years)3.12
Cites / Document (3 Years)3.28
Cites / Document (4 Years)3.16

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #35/272
Percentile 87.13
Quartile Q1
Cardiology and Cardiovascular Medicine in Medicine
Rank #57/387
Percentile 85.27
Quartile Q1
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #65/313
Percentile 79.23
Quartile Q1

IF (Web Of Science)

CARDIAC & CARDIOVASCULAR SYSTEMS
Rank 67/220
Percentile 69.80
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 126/354
Percentile 64.50
Quartile Q2

JCI (Web Of Science)

CARDIAC & CARDIOVASCULAR SYSTEMS
Rank 69/220
Percentile 68.64
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 125/354
Percentile 64.69
Quartile Q2

Quartile History

Similar Journals

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Elevating Research through Expert Analysis
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

Clinica e Investigacion en Arteriosclerosis

Advancing cardiovascular knowledge for a healthier tomorrow.
Publisher: ELSEVIERISSN: 0214-9168Frequency: 6 issues/year

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Cardiovascular Therapeutics

Driving Progress in Cardiovascular Health and Treatment
Publisher: WILEY-HINDAWIISSN: 1755-5914Frequency: 1 issue/year

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

DRUGS IN R&D

Empowering innovation in drug development and research.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Advancing cardiovascular health through innovative pharmacology.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0160-2446Frequency: 12 issues/year

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

CNS DRUGS

Advancing Neuroscience through Innovative Pharmacotherapy
Publisher: ADIS INT LTDISSN: 1172-7047Frequency: 12 issues/year

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

CARDIOVASCULAR RESEARCH

Exploring the complexities of cardiovascular health.
Publisher: OXFORD UNIV PRESSISSN: 0008-6363Frequency: 18 issues/year

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

CIRCULATION JOURNAL

Exploring the Frontiers of Heart Health Research.
Publisher: JAPANESE CIRCULATION SOCISSN: 1346-9843Frequency: 12 issues/year

CIRCULATION JOURNAL, published by the Japanese Circulation Society, stands as a premier platform for cutting-edge research in the fields of Cardiology and Cardiovascular Medicine. With an impressive impact factor placing it in the Q1 quartile for both cardiology and general medicine, this journal is essential for researchers and practitioners seeking to stay at the forefront of cardiovascular science. The journal's accessible open access options ensure that groundbreaking studies are widely disseminated, reflecting its commitment to advancing medical knowledge and improving patient care. Since its inception in 1996, CIRCULATION JOURNAL has fostered a global dialogue on vital cardiovascular issues, making it a vital resource for academics, healthcare professionals, and students alike. With its base in Tokyo, Japan, the journal not only highlights regional advancements but also contributes significantly to the global medical community.

Expert Review of Cardiovascular Therapy

Bridging Research and Practice in Heart Health
Publisher: TAYLOR & FRANCIS INCISSN: 1477-9072Frequency: 12 issues/year

Expert Review of Cardiovascular Therapy is a leading academic journal published by TAYLOR & FRANCIS INC, focusing on innovative and impactful research in the field of cardiovascular medicine. With an ISSN of 1477-9072 and an E-ISSN of 1744-8344, this journal serves as an essential resource for researchers, clinicians, and educators, offering a platform for the dissemination of critical advancements in cardiovascular therapy and internal medicine. Since its inception in 2003, the journal has maintained a reputable standing with a Q2 ranking in various categories including Cardiology and Cardiovascular Medicine, reflecting its influence and rigor in the field. The journal, which is based in the United Kingdom, does not currently offer Open Access options, ensuring that its content is accessible primarily to subscribers. With its commitment to high-quality, peer-reviewed articles, Expert Review of Cardiovascular Therapy is dedicated to bridging the gap between experimental research and clinical application, thereby enhancing patient care and therapeutic outcomes in cardiovascular health.

Archives of Cardiovascular Diseases

Advancing cardiovascular health through groundbreaking research.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 1875-2136Frequency: 12 issues/year

The Archives of Cardiovascular Diseases, published by Elsevier Masson, stands as a leading journal in the field of cardiology and cardiovascular medicine, with an impressive impact factor that underscores its relevance and influence. This esteemed journal, recognized in the Q2 category for both cardiology and miscellaneous medicine, aims to disseminate groundbreaking research, innovative methodologies, and clinical advancements that can shape the future of cardiovascular health. With its diverse array of open access options, researchers and students alike have the ability to engage with high-quality content, ensuring that cutting-edge findings are accessible globally. Since its inception in 2008, the journal has actively contributed to the advancement of knowledge in cardiovascular diseases, fostering collaboration among clinicians, researchers, and educators. Headquartered in Paris, France, Archives of Cardiovascular Diseases remains committed to enhancing our understanding of cardiovascular health and improving patient outcomes worldwide.